Initial Trials Indicate Reduced Intensity Stem Cell Transplant Safe For Scleroderma Patients
Mon, 13 Nov 2006 08:00 AM EST
... A phase I trial of non-myeloablative or reduced intensity hematopoietic stem cell transplantation (HSCT) in patients with systemic sclerosis (scleroderma) has proven safe and well tolerated, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Washington, DC. [click link for full article] ...
Related Topics
- Scleroderma
- Stem Cell Research
- Bone Marrow
- Stem Cells and Stem Cell Transplantation
- Stem Cells/Stem Cell Transplantation
- Peripheral Blood Stem Cells
- Multiple Myeloma
- Myeloma, Multiple
- Transplantation
- Umbilical Cord Blood
- Blood Cells
- Sickle Cell Anemia
- Systemic Lupus Erythematosus
- Safe Motherhood
- Cornea & Corneal Disease
- Small Cell Lung Cancer
- Sickle Cell
- Ampicillin
- Skin Cancer
- Vaccinations For HIV/AIDs Patients

Not Signed In -


